Research & Teaching Faculty

Default Header Image

Vanadium in diabetes: 100 years from Phase 0 to Phase I

TitleVanadium in diabetes: 100 years from Phase 0 to Phase I
Publication TypeJournal Article
Year of Publication2006
AuthorsThompson, KH, Orvig, C
JournalJournal of Inorganic Biochemistry
Volume100
Pagination1925-1935
Date PublishedDec
ISBN Number0162-0134
Abstract

A little over one hundred years ago, a vanadium-containing compound was assessed clinically for use in treatment of human diabetic patients. The results were somewhat ambiguous, but nonetheless, intriguing. In 2000, the first Phase I clinical trial of a designed vanadium-based pharmaceutical agent (bis(ethylmaltolato)oxovanadium(IV), BEOV), was completed by Medeval Ltd., Manchester, UK. Results here, too, were promising, but not without some difficult remaining questions. In this review, we look back at the many questions asked and answered regarding vanadium’s glucose-enhancing potential, its biodistribution and biomolecular transformation, and its mechanism(s) of action, and consider some of the newest developments in the field, including novel delivery methods for vanadium in diabetes treatment. (c) 2006 Elsevier Inc. All rights reserved.

URL<Go to ISI>://000242919600003